World-class expertise.
Leading-edge technologies.
Record-breaking success.
We’re taking medicine to new heights.
At Nimbus, exquisite selectivity is at the core of everything we do. From people to targets to molecules to partners, our meticulous choices enable us to successfully design and develop small molecule medicines capable of improving patients’ lives. And we have a track record to prove it.
Discover our unique approach to target selection, computational drug design, translational medicine, and clinical development.
Explore our highly selective small molecule medicines for oncology, immunology, and metabolic indications.
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
